Lundbeck/Takeda Advance Novel Anxiety Candidate To Phase III

H. Lundbeck and Takeda Pharmaceutical have initiated Phase III trials of their novel mood and anxiety disorders candidate Lu AA21004 roughly four months after inking a co-development deal, the firms announced Dec. 18